Abstract

Novel antibiotic treatments are in increasing demand to tackle life-threatening infections from bacterial pathogens. In this study, we report the use of a potent battacin lipopeptide as an antimicrobial gel to inhibit planktonic and mature biofilms of S. aureus and P. aeruginosa. The antimicrobial gels were made by covalently linking the N-terminal cysteine containing lipopeptide (GZ3.163) onto the polyethylene glycol polymer matrix and initiating gelation using thiol-ene click chemistry. The gels were prepared both in methanol and in water and were characterised using rheology, Fourier transform infrared (FT-IR) spectroscopy and scanning electron microscopy (SEM). Antibacterial and antibiofilm analyses revealed that the gels prepared in methanol have better antibacterial and antibiofilm activity. Additionally, a minimum peptide content of 0.5 wt% (relative to polymer content) is required to successfully inhibit the planktonic bacterial growth and disperse mature biofilms of P. aeruginosa and S. aureus. The antibacterial activity of these lipopeptide gels is mediated by a contact kill mechanism of action. The gels are non-haemolytic against mouse red blood cells and are non-cytotoxic against human dermal fibroblasts. Findings from this study show that battacin lipopeptide gels have the potential to be developed as novel topical antibacterial agents to combat skin infections, particularly caused by S. aureus.

Highlights

  • IntroductionWe are increasingly reliant on “last-resort” antibiotics as “first-line” treatments against multi-drug resistant (MDR) pathogens

  • Antimicrobial resistance is one of the biggest health risks faced by modern society

  • polyethylene glycol (PEG) based antimicrobial hydrogels have been extensively studied in the literature and PEG based materials are ideal for antibacterial surfaces mainly due to their anti-adhesive property attributed to the high mobility and steric hindrance of the ethylene glycol moieties as well as due to low host immune response [14,19,20,21,22,23]

Read more

Summary

Introduction

We are increasingly reliant on “last-resort” antibiotics as “first-line” treatments against multi-drug resistant (MDR) pathogens. To further exacerbate this problem, several of these MDR pathogens aggregate and colonise surfaces, forming bacterial biofilms that are up to 1000 times more resistant to antibiotic treatments than their planktonic counterparts [1]. According to the 2013 report published by the Centre for Disease Control and Preventions each year in the United States of America, at least 2 million people become infected with resistant bacterial pathogens and at least 23,000 people die as a direct result of MDR bacterial infections [2].

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call